889852-02-2

Usage

Uses

Used in Pharmaceutical Industry:
5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one is used as an active pharmaceutical ingredient (API) for the development of new drugs. Its unique molecular structure and chemical properties make it a promising candidate for the treatment of various diseases and disorders.
Used in Medicinal Chemistry Research:
5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one is also used as a research tool in medicinal chemistry, where it can be employed to study the structure-activity relationships of various drug candidates. Its unique chemical features can provide valuable insights into the design and optimization of new therapeutic agents.
Used in Drug Impurity Analysis:
5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one can be used as an impurity in the synthesis of other pharmaceutical compounds. The analysis and control of impurities are crucial for ensuring the safety, efficacy, and quality of drug products.
Used in Drug Delivery Systems:
5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one can also be used in the development of drug delivery systems, where it can serve as a carrier or a component of a drug delivery platform. Its unique chemical properties may enable the design of innovative drug delivery systems with improved performance and therapeutic outcomes.

Upstream product

• 265121-01-5 [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]phosphonic acid bis(phenylmethyl)ester 
• 538-37-4 dibenzyl phosphochloridate 
• 990-91-0 dibenzyl [[bis(benzyloxy)phosphoryl]oxy]phosphonate 
• 67-56-1 methanol 

Downstream Products

• 265121-04-8 {3-[[2(R)-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-morpholin-4-yl]methyl]-5-oxo-4,5-dihydro-[1,2,4]-triazol-1-yl}phosphonic acid N-methyl-L-glucamine salt 

Relevant academic research and scientific papers

Preparation method of fosaprepitant dimeglumine pharmaceutical salt

The invention belongs to the technical field of medicine chemistry, and particularly relates to a novel preparation method of fosaprepitant dimeglumine. According to the preparation method, triethyl silane is used for replacing hydrogen, and high-pressure

A process for the preparation of [3 - [(2 R) - [(1 R) - 1 - [3, 5 - di (trifluoromethyl) phenyl] ethoxy] - 3 (S)- (4 - fluorophenyl) morpholine - 4 - yl] methyl] - 5 - oxo - 4, 5 - dihydro - [1, 2, 4] - triazole - 1 - yl] phosphine acid animal pen ester new method

The invention relates to a new method for preparing fosaprepitant intermediate, namely, [3-[(2R)-[(1R)-1-(3, 5-bi (trifluoromethyl) phenyl] ethyoxyl]-3 (S)-(4-fluorophenyl) morpholine 4-group] methyl]-5-oxo-4, 5-dihydro-[1, 2, 4]-triazole-1-group] phosphonic acid-benzyl ester. The compound is an important medicine intermediate, and is used for preparing antiemetic drug fosaprepitant. The new method comprises the steps of: enabling newly prepared phosphorylation agent dibenzyl phosphorus oxychloride and aprepitant to have reaction in organic solvent under the action of steric hindrance alkali, treating the product with methyl alcohol to obtain the fosaprepitant intermediate. The method is simple in operation and low in cost, thus being more suitable for industrial production.

PROCESS FOR [3-[3(R)-[(R)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]HOXY]-3(S)-(4-FLUOROPHENYL)MORPHOLIN-4-YL-5-OxO-4,5-DIHYDRO-[1,2,4]-TRIAZOL-1-YL PHOSPHONIC ACID

The present invention is concerned with a process for the preparation of the compound {3-[2(R)-[(1R)-1-[3,5-bis(tri-fluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-morpholin-4-yl]methyl]-5-oxo-4,5-dihydro-[1,2,4]-triazol-1-yl}phosphonic acid, and pharmaceutically acceptable salts thereof. This compound is useful as a substance P (neurokinin-1) receptor antagonist. In particular, the compound is useful e.g., in the treatment of emesis and inflammatory diseases.